In this review article, he also reviewed the role of immunotherapy in small cell lung cancer. Small cell lung cancer remains most difficult cancers very few therapies. After reviewing several clinical health, the authors concluded that combination of chemotherapy with Ipilimumab is not advisable. There is no survival advantage in very high toxicity profile. On the other hand, the combination of ipilimumab and nivolumab is recommended as durable responses are noted. Further data from atezolizumab and pembrlizumab are still maturing.